摘要
目的:分析贝伐珠单抗致胃肠道穿孔(gastrointestinal perforation,GIP)的发生规律及特点,为安全用药提供参考。方法:检索2004年至2015年3月国内外学术期刊收载的贝伐珠单抗致GIP文献进行分析。结果:17例不良反应中,男性9例,女性8例,年龄≥65岁的老年患者7例(41.18%);17例GIP患者中,发生在前15周疗程内有13例(76.47%)。有7例采用非手术保守治疗,10例采取手术治疗,死亡7例。结论:临床医师应了解贝伐珠单抗致GIP的规律和特点,加强用药监测,以便及时发现和处理GIP。
Objective： To analyze the general patterns and characteristics of gastrointestinal perforation（ GIP） induced by bevacizumab,providing a reference for clinical medication. Methods： Bevacizumab-induced GIP reported from 2004 to March 2015 via searching CNKI,VIP and Pubmed were collected and analyzed statistically. Results： Totally 17 patients of GIP caused by bevacizumab were collected,including 9 men and 8 women. Patients over the age of 65 years showed the higher incidence（ n = 7,41. 18%）. In 17 patients with GIP,13（ 76. 47%） developed within the first 15 weeks of the treatment. There were 7 patients receiving non-surgical conservative treatment and 10 receiving surgical treatment. Of the 17 GIP patients,7 patients died. Conclusion： Clinicians should be aware of rules and characteristics of GIP induced by bevacizumab,and tighten monitoring its using to detect and deal with GIP.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2016年第5期594-596,共3页
Chinese Journal of New Drugs
关键词
贝伐珠单抗
胃肠道穿孔
文献分析
bevacizumab
gastrointestinal perforation
literature analysis
